Yousaf Ali, MBBS
- PROFESSOR | Medicine, Rheumatology
Dr. Ali is a Professor in the Mount Sinai Department of Medicine and Chief of the Division of Rheumatology at Mount Sinai West. He is a graduate of the Royal Free Hospital School of Medicine in London. After two years of postgraduate training in the UK, he moved to the US and did his Internal Medicine training at OHSU in Portland, Oregon. He completed his fellowship training in Rheumatology at Yale University and is board certified in both Rheumatology and Internal Medicine. For three years he was the Vice Chair of Faculty Affairs in the Department of Medicine.
Prior to Mount Sinai, Dr. Ali was in practice in Providence, Rhode Island for nine years, where he was an Assistant Clinical Professor of Medicine at Brown University. He is the recipient of a multitude of awards, including the prestigious Beckwith Family award for outstanding teaching. He has published numerous articles, book chapters, and has lectured widely on Rheumatoid arthritis, Osteoporosis, Gout and Osteoarthritis. His current research involves cardiovascular inflammation as it relates to Gout and he is PI on several studies including novel anticytokine targets in non-radiographic spondyloarthropathy and the role of PET imaging in patients with Rheumatoid Arthritis.
Read Dr. Ali's blog on psoriatic arthritis here.
- Ankylosing Spondylitis
- Behcet's Disease
- Polymyalgia Rheumatica And Giant Cell Arteritis
- Reiter's Syndrome
- Rheumatoid Arthritis
- Sjogren's Syndrome
- Systemic Lupus Erythematosus
- Temporal Arteritis
- Wegener's Granulomatosis
BM, Royal Free Hospital Sch of Medicine
MD, Royal Free Hospital School of Medicine. University of London
Residency, Internal Medicine, Oregon Health Sciences University
2021 IME Excellence in Teaching Awards
Stanley G. Seckler Award for Clinical and Educational Excellence in Medicine
Best Doctors in NY
Best Doctors in Rhode Island
Beckwith Family Award for outstanding teaching
Teaching Recognition Award
Top Doctors in New York
Dr Ali is currently PI on several trials investigating new treatments for SLE and RA. He is also developing a patient centric app to predict flares in RA that should improve care and outcome.
Embrace Study: phase 3/4, multi-center, randomized, double-blind, placebo-controlled,52-week study to evaluate the efficacy and safety of belimumab (HGS1006) in adult subjects of black race with SLE
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of CNTO 136 (sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Subjects with Active Rheumatoid Arthritis Despite Anti-TNF Therapy